Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IOVA Stock Forecast 2026-2027
$4.66
Current Price
$2.08B
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to IOVA Price Targets
+200.4%
To High Target of $14.00
+103.9%
To Median Target of $9.50
-14.2%
To Low Target of $4.00
IOVA Price Momentum
+10.2%
1 Week Change
+18.6%
1 Month Change
+99.1%
1 Year Change
+70.7%
Year-to-Date Change
-17.2%
From 52W High of $5.63
+164.8%
From 52W Low of $1.76
📊 TOP ANALYST CALLS
Did IOVA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Iovance is one of their latest high-conviction picks.
Latest IOVA Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, IOVA has a bullish consensus with a median price target of $9.50 (ranging from $4.00 to $14.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $4.66, the median forecast implies a 103.9% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Geulah Livshits at Chardan Capital, projecting a 200.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IOVA Analyst Ratings
8
Buy
2
Hold
0
Sell
IOVA Price Target Range
Low
$4.00
Average
$9.50
High
$14.00
Current: $4.66
Latest IOVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IOVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| May 7, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $14.00 |
| Apr 10, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 5, 2026 | UBS | Neutral | Maintains | $N/A | |
| Mar 3, 2026 | Citizens | Market Outperform | Upgrade | $N/A | |
| Feb 25, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 25, 2026 | Citizens | Market Outperform | Upgrade | $N/A | |
| Dec 17, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Nov 24, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Nov 6, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Oct 29, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 8, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Aug 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jul 23, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 16, 2025 | UBS | Neutral | Downgrade | $N/A | |
| May 12, 2025 | Goldman Sachs | Buy | Maintains | $N/A | |
| May 12, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| May 12, 2025 | Barclays | Overweight | Maintains | $N/A | |
| May 9, 2025 | JMP Securities | Market Perform | Downgrade | $N/A |
Iovance Biotherapeutics, Inc. (IOVA) Competitors
The following stocks are similar to Iovance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iovance Biotherapeutics, Inc. (IOVA) Financial Data
Iovance Biotherapeutics, Inc. has a market capitalization of $2.08B with a P/E ratio of -4.3x. The company generates $285.61M in trailing twelve-month revenue with a -123.9% profit margin.
Revenue growth is +44.8% quarter-over-quarter, while maintaining an operating margin of -113.5% and return on equity of -47.5%.
Valuation Metrics
Market Cap
$2.08B
Enterprise Value
$1.85B
P/E Ratio
-4.3x
PEG Ratio
0.1x
Price/Sales
7.3x
Growth & Margins
Revenue Growth (YoY)
+44.8%
Gross Margin
+40.5%
Operating Margin
-113.5%
Net Margin
-123.9%
EPS Growth
+44.8%
Financial Health
Cash/Price Ratio
+15.1%
Current Ratio
3.6x
Debt/Equity
6.6x
ROE
-47.5%
ROA
-23.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Iovance Biotherapeutics, Inc. (IOVA) Business Model
About Iovance Biotherapeutics, Inc.
What They Do
Develops innovative TIL cell therapies for cancer.
Business Model
The company operates in the biopharmaceutical sector, focusing on the development and commercialization of tumor-infiltrating lymphocyte (TIL) therapies. It generates revenue primarily through the sale of its FDA-approved product, Amtagvi (lifileucel), and aims to expand its market presence by advancing clinical programs for various solid tumors.
Additional Information
Iovance's therapies are designed as personalized, one-time treatments that utilize the patient's immune system to combat cancer. The company manufactures its products at a specialized facility in Philadelphia and collaborates with research institutions and pharmaceutical partners to enhance its therapeutic pipeline.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
975
CEO
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Country
United States
IPO Year
2017
Website
www.iovance.comIovance Biotherapeutics, Inc. (IOVA) Latest News & Analysis
Latest News
Quick Summary
Heartflow leads in non-invasive coronary diagnostics with over 1,450 accounts, while Iovance Biotherapeutics develops personalized cancer therapies and shows significant revenue growth.
Why It Matters
Heartflow's AI advancements and solid client base signal strong market positioning, while Iovance's innovative therapies and revenue growth highlight potential for substantial returns in biotech.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Amgen has a revenue base of approximately $36.7 billion and strong net income, while Iovance Biotherapeutics presents high growth potential with its advanced cancer cell therapies.
Why It Matters
Amgen's stable revenue and net income signal financial health, while Iovance's growth potential in advanced cancer therapies presents investment opportunities in biotech.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Iovance Biotherapeutics approved inducement stock options for 140,860 shares to 27 new non-executive employees as of June 18, 2026.
Why It Matters
The grant of stock options to new employees may indicate Iovance's growth strategy and confidence in its future, potentially affecting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IOVA projects $350M–$370M in 2026 revenue, a 36% increase. Q2'26 is expected to be a record quarter, with expansion into new indications and markets supporting growth.
Why It Matters
IOVA's strong revenue guidance and expansion into new indications signal growth potential, while a favorable FDA may expedite approvals, enhancing investor confidence in future performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
1 month ago
Quick Summary
Iovance Biotherapeutics shares have risen over the past year but are down nearly 80% over five years. Recent sales growth and a solid cash position may indicate improving prospects.
Why It Matters
Iovance's recent sales growth and improved cash position may signal recovery, potentially boosting investor confidence, despite its significant long-term decline.
Source: The Motley Fool
Market Sentiment:
Positive
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
1 month ago
Quick Summary
Australia has approved its first T cell therapy for solid tumors, marking a new treatment option for advanced melanoma after anti-PD-1 and targeted therapies.
Why It Matters
The approval of the first T cell therapy for advanced melanoma in Australia signals innovation in cancer treatment, potentially increasing market opportunities and impacting biotech stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IOVA Stock
What is Iovance Biotherapeutics, Inc.'s (IOVA) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Iovance Biotherapeutics, Inc. (IOVA) has a median price target of $9.50. The highest price target is $14.00 and the lowest is $4.00.
Is IOVA stock a good investment in 2027?
According to current analyst ratings, IOVA has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IOVA stock?
Wall Street analysts predict IOVA stock could reach $9.50 in the next 12 months. This represents a 103.9% increase from the current price of $4.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iovance Biotherapeutics, Inc.'s business model?
The company operates in the biopharmaceutical sector, focusing on the development and commercialization of tumor-infiltrating lymphocyte (TIL) therapies. It generates revenue primarily through the sale of its FDA-approved product, Amtagvi (lifileucel), and aims to expand its market presence by advancing clinical programs for various solid tumors.
What is the highest forecasted price for IOVA Iovance Biotherapeutics, Inc.?
The highest price target for IOVA is $14.00 from Geulah Livshits at Chardan Capital, which represents a 200.4% increase from the current price of $4.66.
What is the lowest forecasted price for IOVA Iovance Biotherapeutics, Inc.?
The lowest price target for IOVA is $4.00 from at , which represents a -14.2% decrease from the current price of $4.66.
What is the overall IOVA consensus from analysts for Iovance Biotherapeutics, Inc.?
The overall analyst consensus for IOVA is bullish. Out of 4 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $9.50.
How accurate are IOVA stock price projections?
Stock price projections, including those for Iovance Biotherapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:44 AM UTC